ACL
AU CLINICAL LABS ORDINARYAustralian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
ACL
ACL
AU CLINICAL LABS ORDINARY
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 6.73% | — |
| 10 July | 6.81% | — |
| 9 July | 7.06% | — |
| 8 July | 7.31% | — |
| 7 July | 7.56% | — |
| 6 July | 7.69% | — |
| 3 July | 7.76% | — |
| 2 July | 7.82% | — |
| 1 July | 7.83% | — |
Au Clinical Labs (ACL) Short Interest Summary
Au Clinical Labs (ACL) currently has 6.73% of its shares sold short (12.6 million shares, worth approximately $30.3 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes ACL the #44 most shorted stock on the ASX most shorted list. Short interest in ACL is down 0.96% over the past week and down 1.48% over the past month. ACL is part of the Health Care sector on the ASX.
Recent ACL Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 6.73% | 12.6M | $2.23 |
| 10 July 2026 | 6.81% | 12.7M | $2.22 |
| 9 July 2026 | 7.06% | 13.2M | $2.22 |
| 8 July 2026 | 7.31% | 13.6M | $2.23 |
| 7 July 2026 | 7.56% | 14.1M | $2.28 |
| 6 July 2026 | 7.69% | 14.3M | $2.29 |
| 3 July 2026 | 7.76% | 14.5M | $2.24 |
| 2 July 2026 | 7.82% | 14.6M | $2.23 |
| 1 July 2026 | 7.83% | 14.6M | $2.24 |
| 30 June 2026 | 8.02% | 15.0M | $2.24 |
ACL Short Selling — Frequently Asked Questions
What is Au Clinical Labs (ACL)'s current short interest?
Au Clinical Labs (ACL) currently has a short interest of 6.73% of total shares outstanding. This means 6.73% of ACL's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is ACL heavily shorted on the ASX?
ACL has a moderate level of short interest at 6.73%. While below the heavily shorted threshold of 10%, this indicates notable bearish positioning. ACL is currently ranked #44 among the most shorted stocks on the ASX.
What does short interest mean for ACL investors?
Short interest in ACL shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 6.73%, ACL's short interest is at a moderate level. See our short squeeze candidates and days to cover analysis for more context.
Where does this ACL short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for ACL.